Personalis® to Present at the AMP Annual Meeting 2020
16 11월 2020 - 11:00PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced that the company will present data from
its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting
from Nov 16-20, 2020.
The poster presentation, titled “An exome and transcriptome
based NeXT DxTM test enables therapy selection for cancer patients
and offers insights into emerging composite biomarkers for
immunotherapy” will be presented on Tuesday, Nov 17th between 1-2pm
EST. The NeXT Dx test utilizes Personalis’ ImmunoID NeXT Platform®,
the first platform to enable comprehensive analysis of both a tumor
and its immune microenvironment from a single sample. The
Personalis NeXT Dx Test provides a diagnostic report to the
ordering provider which includes genomic alterations identified in
247 cancer-related genes, therapy recommendations, clinical trial
matching and results from immunotherapy-related biomarkers such as
microsatellite instability (MSI) status and exome-wide tumor
mutational burden (TMB). Research data supporting identification of
novel biomarkers from tumor exome and transcriptome can be provided
upon physician’s request.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veteran Program (VA MVP). In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing our
biopharmaceutical customers with information on approximately
20,000 human genes, together with the immune system, from a single
tissue sample. The Personalis Clinical Laboratory is GxP-aligned as
well as CLIA’88-certified and CAP-accredited. For more information,
please visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform, Personalis’ services for the VA MVP,
the company’s business opportunities, leadership or growth, or
other future events. Such forward-looking statements involve risks
and uncertainties, including those related to the COVID-19
pandemic, that could cause actual results to differ materially from
any anticipated results or expectations expressed or implied by
such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including the company’s most
recent reports on Forms 8-K, 10-K and 10-Q, and include those
listed under the caption “Risk Factors.” Personalis disclaims any
obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005468/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678
Media Contact: Jennifer Havlek pr@personalis.com
https://www.personalis.com/
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024